{"entity":{"id":"nct06683703","kind":"trial","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","aka":[],"tldr":"A phase 2 trial of utidelone and bevacizumab in lung cancer, run by Beijing Biostar Pharmaceuticals Co., Ltd., not yet recruiting.","summary":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases is a phase 2, randomised interventional study registered as NCT06683703 by Beijing Biostar Pharmaceuticals Co., Ltd., with a registry enrolment figure of 118 participants, started 2024-12-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Utidelone combined with Bevacizumab; Utidelone; Utidelone combined with Bevacizumab; Utidelone combined with Bevacizumab. Conditions listed: Non-small Cell Lung Cancer Patients with Brain Metastases. Primary outcome: Intracranial objective response rate (iORR) according to the RECIST 1.1.; Determining the Expansion Dose. Lung eligibility wording from the registry: \"non-squamous non-small cell lung cancer (adenocarcinoma or adenocarcinoma component dominant) with brain parenchymal metastasis confirmed by histology or cytology, but unsuitable or refused local treatment/surgery;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06683703","url":"https://clinicaltrials.gov/study/NCT06683703"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["utidelone","bevacizumab"],"companies":["biostar-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06683703","phase":"2","setting":"Phase II Clinical Trial on the Efficacy and Safety of Utidelone Combined with Bevacizumab in Patients with Non-small Cell Lung Cancer with Brain Metastases.","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","enrolled":118,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06683703/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/"}],"company":[{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}